IMRN IMMURON |
$2.27
+13.3% |
+21.1%
 |
IMM-529
Oral polyclonal antibody, targeting toxin B in the human gut and neutralises main virulence factors of Clostridium infection
|
IND
|
10/8/2025 - IND Submission
Immuron Limited announce that it has submitted an Investigational New Drug (IND) application to th…
Full Summary
|
AQST Aquestive Therapeutics |
$6.20
+3.9% |
+23.8%
 |
Anaphylm
For epinephrine prodrug candidate product
|
|
10/8/2025 - Provided Update
Aquestive Therapeutics, Inc announced the United States Patent and Trademark Office (USPTO) has iss…
Full Summary
|
MDT Medtronic |
$97.88
-0.5% |
+5.4%
 |
Hugo
for gynecological procedures
|
|
10/8/2025 - Clinical Study
Medtronic plc announced the start of the Embrace Gynecology investigational device exemption (IDE) …
Full Summary
|
ABEO Abeona Therapeutics |
$5.54
+5.5% |
-17.3%
 |
ZEVASKYN
To Treat Wounds in Painful Skin Disorder
|
|
10/8/2025 - Provided Update
Abeona Therapeutics Inc announced activation of Children's Colorado as the newest Qualified Treatme…
Full Summary
|
TRVI Trevi Therapeutics |
$9.82
+2.8% |
+29.2%
 |
nalbuphine ER
chronic cough in patients with idiopathic pulmonary fibrosis (IPF)
|
|
10/8/2025 - Abstract Presentation
Trevi Therapeutics, announced the acceptance of two abstracts for presentation at the CHEST 2025 An…
Full Summary
|
AARD Aardvark Therapeutics |
$17.13
-1.6% |
+108.9%
 |
ARD-101
for Prader-Willi Syndrome
|
|
10/8/2025 - Provided Update
Aardvark Therapeutics, Inc announces alignment with the U.S. Food and Drug Administration (FDA) on…
Full Summary
|
HOWL Werewolf Therapeutics |
$1.88
-2.6% |
+41.4%
 |
WTX-124
Solid Tumors
|
Fast Track
|
10/8/2025 - Designation Grant
Werewolf Therapeutics, Inc. announced that the Company has received Fast Track Designation for the …
Full Summary
|
ATXS Astria Therapeutics |
$8.40
+12.4% |
+13.1%
 |
Navenibart
For the Treatment of Hereditary Angioedema
|
Phase 3
|
10/8/2025 - Initiation
Astria Therapeutics, Inc. announced the initiation of the Phase 3 ORBIT-EXPANSE long-term trial of …
Full Summary
|
RIGL Rigel Pharmaceuticals |
$28.76
-2.5% |
-29.6%
 |
R289
For Lower-Risk MDS
|
Phase 1b
|
10/8/2025 - Enrollment Update
Rigel Pharmaceuticals, Inc nnounced the first patient has been enrolled in the dose expansion phase…
Full Summary
|
AZN AstraZeneca |
$85.38
-0.6% |
+4.7%
 |
Bax24
Patients with treatment-resistant hypertension (rHTN)
|
|
10/7/2025 - Results
AstraZeneca announced Positive high-level results from the Bax24 Phase III trial showed baxdrostat …
Full Summary
|
ACET Adicet Bio |
$0.93
+8.9% |
+21.7%
 |
ADI-001
B cell non-Hodgkin's lymphoma (NHL)
|
|
10/7/2025 - Efficacy and Safety Data
Adicet Bio, Inc announced initial safety and efficacy data from the first seven patients dosed with …
Full Summary
|
LLY Eli Lilly and Company |
$845.55
+0.2% |
+14.5%
 |
mirikizumab-mrkz
For Crohn's disease
|
|
10/7/2025 - New Data
New data from Eli Lilly and Company showed Omvoh (mirikizumab-mrkz) is the first and only interleuki…
Full Summary
|
AKRO Akero Therapeutics |
$46.49
+1.1% |
+4.3%
 |
Efruxifermin
Non-alcoholic steatohepatitis (NASH)
|
|
10/7/2025 - Upcoming presentations
Akero Therapeutics, Inc. announced two upcoming oral presentations and a poster presentation at th…
Full Summary
|
ENTA Enanta Pharmaceuticals |
$11.30
+2.0% |
+26.8%
 |
EDP-323
Eduction in RSV replication with picomolar potency in primary human bronchial epithelial cells against RSV A and B
|
|
10/7/2025 - Data
Enanta Pharmaceuticals, Inc announced that data for EDP-323, it's oral, once-daily L-protein inhibi…
Full Summary
|
ENTA Enanta Pharmaceuticals |
$11.30
+2.0% |
+26.8%
|
zelicapavir
For respiratory syncytial virus
|
|
10/7/2025 - Data
Enanta Pharmaceuticals, Inc announced that data for zelicapavir, its oral, once-daily, N-protein i…
Full Summary
|
PLSE Pulse Biosciences |
$19.94
+0.4% |
+32.6%
 |
nPulse™ Cardiac Surgical System
treatment of atrial fibrillation (AF)
|
|
10/7/2025 - Upcoming presentations
Pulse Biosciences, Inc. announced the upcoming presentation of early clinical data on the treatment…
Full Summary
|
NVAX Novavax |
$8.90
-3.5% |
+15.1%
 |
Nuvaxovid
Covid-19
|
|
10/7/2025 - Provided Update
Novavax, Inc. announced that it has completed the transfer of the marketing authorization for its CO…
Full Summary
|
ARWR Arrowhead Pharmaceuticals |
$36.94
+1.1% |
+36.0%
 |
ARO-DIMER-PA
for the Treatment of Mixed Hyperlipidemia
|
|
10/7/2025 - Provided Update
Arrowhead Pharmaceuticals, Inc. announced that it has filed a request for regulatory clearance to i…
Full Summary
|
JNJ Johnson & Johnson |
$189.75
+0.5% |
+6.4%
 |
apalutamide
For the treatment of prostate cancer (nmCRPC)
|
|
10/7/2025 - Presentation
Kairos Pharma, Ltd. announced that it has been selected to present at the European Society for Medic…
Full Summary
|
AVIR Atea Pharmaceuticals |
$3.10
+4.4% |
-4.6%
 |
Bemnifosbuvir
COVID-19
|
|
10/7/2025 - New Data
Atea Pharmaceuticals, Inc. announced that new data will be presented supporting the combination reg…
Full Summary
|
ABUS Arbutus Biopharma |
$4.18
-2.6% |
+2.2%
 |
AB-101
Oral PD-L1 inhibitor
|
|
10/7/2025 - Abstract
Arbutus Biopharma announced that three abstracts featuring imdusiran data and one abstract featurin…
Full Summary
|
GALT Galectin Therapeutics |
$4.74
-0.6% |
+1.5%
 |
Belapectin (Formerly GR-MD-02)
Non-alcoholic steatohepatitis (NASH) with cirrhosis
|
|
10/7/2025 - Provided Update
Galectin Therapeutics announced participation in the AASLD Liver Meeting 2025.
Full Summary
|
INVA Innoviva |
$17.37
+1.0% |
-15.1%
 |
Zoliflodacin
For the Treatment of Uncomplicated Gonorrhea
|
|
10/7/2025 - Data
Innoviva, Inc. announced that it will deliver data from six presentations at IDWeek 2025, including …
Full Summary
|
COCH Envoy Medical |
$0.93
-41.5% |
-29.0%
 |
Acclaim
for Breakthrough Hearing Device
|
|
10/7/2025 - FDA approved
Envoy Medical, announced that it received approval from the U.S. Food and Drug Administration (FDA) …
Full Summary
|
JNJ Johnson & Johnson |
$189.75
+0.5% |
+6.4%
|
ACUVUE OASYS MAX 1-Day
for Astigmatism
|
|
10/7/2025 - New Data
Johnson & Johnson announced new data on the ACUVUE OASYS MAX 1-Day for ASTIGMATISM contact lenses wh…
Full Summary
|
JNJ Johnson & Johnson |
$189.75
+0.5% |
+6.4%
|
Icotrokinra
For adults and adolescents with plaque psoriasis
|
Phase 2b
|
10/7/2025 - Results
Johnson & Johnson announced additional Week 12 results from the Phase 2b ANTHEM-UC study of icotroki…
Full Summary
|
JNJ Johnson & Johnson |
$189.75
+0.5% |
+6.4%
|
Guselkumab
For Treatment Of Adults With Moderately To Severely Active Ulcerative Colitis
|
Phase 3
|
10/7/2025 - New Data
Johnson & Johnson announced new 48-week data from the Phase 3 ASTRO study evaluating TREMFYA® (guse…
Full Summary
|
CTXR Citius Pharmaceuticals |
$1.29
-8.2% |
+5.3%
 |
LYMPHIR
For the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma
|
|
10/7/2025 - Provided Update
Citius Oncology, Inc. announced it is actively engaging with regional distribution partners to make…
Full Summary
|
VRCA Verrica Pharmaceuticals |
$4.42
-4.1% |
-12.6%
 |
VP-315
For the Treatment of Basal Cell Carcinoma
|
|
10/7/2025 - Presentation
Verrica Pharmaceuticals announced that it will be presenting both an oral presentation and a poster…
Full Summary
|
IMMX Immix Biopharma |
$2.54
+1.2% |
+17.1%
 |
NXC-201
NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.
|
|
10/7/2025 - Presentation
Immix Biopharma, Inc announced that it will present a NXC-201 abstract at the upcoming American Soc…
Full Summary
|
CLPT ClearPoint Neuro |
$29.60
+12.2% |
+170.8%
 |
ClearPoint Prism Neuro Laser Therapy System
Brain Tumor Laser Therapy
|
Phase 1/2
|
10/7/2025 - Results
ClearPoint Neuro, Inc announced results from a Phase I-II clinical study at Skåne University Hospit…
Full Summary
|
AZN AstraZeneca |
$85.38
-0.6% |
+4.7%
|
Datopotamab deruxtecan (Dato-DXd)
Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
|
|
10/6/2025 - Positive Results
AstraZeneca and Daiichi Sankyo announced Positive high-level results from the TROPION-Breast02 Phase…
Full Summary
|
MRK Merck & Co., Inc. |
$86.39
-1.4% |
+2.7%
 |
MK-7240
In Inflammatory Bowel Disease
|
Phase 2b
|
10/6/2025 - Study Initiation
Merck announced it has initiated three Phase 2b trials evaluating the safety and efficacy of tuliso…
Full Summary
|
LYRA Lyra Therapeutics |
$7.72
+1.7% |
+17.0%
 |
LYR-210
Chronic Rhinosinusitis
|
Phase 3
|
10/6/2025 - Upcoming presentations
Lyra Therapeutics, Inc. announced the Company's clinical plan and upcoming oral presentation of res…
Full Summary
|
CLRB Cellectar Biosciences |
$4.78
-6.8% |
-5.0%
 |
Iopofosine I-131
Pediatric Brain and Solid Tumors
|
European Commission Conditional Marketing Authorization
|
10/6/2025 - Marketing authorization
Cellectar Biosciences announced that after a scientific advice procedure, the Scientific Advice Wor…
Full Summary
|
TNGX Tango Therapeutics |
$6.91
-5.2% |
+1.5%
 |
TNG260
Immunotherapy of Cancer
|
|
10/6/2025 - Poster Presentation
Tango Therapeutics, Inc. announced that the company will have three poster presentations at the Soci…
Full Summary
|
XCUR Exicure |
$5.32
+23.4% |
+23.7%
 |
burixafor
In Multiple Myeloma
|
|
10/6/2025 - Provided Update
Exicure's ongoing Phase 2 study (NCT05561751) is a randomized, open-label, multicenter trial evaluat…
Full Summary
|
CDNA CareDx |
$14.79
+0.8% |
+10.9%
 |
AlloSeq HCT
Chimerism testing kit for Hematopoietic Cell Transplantation
|
|
10/6/2025 - Provided Update
CareDx, Inc. announced new innovations and products that will be featured at The American Society …
Full Summary
|
RGNX REGENXBIO |
$12.22
+16.3% |
+28.9%
 |
surabgene lomparvovec
for Wet AMD
|
|
10/6/2025 - Enrollment Update
REGENXBIO Inc. nnounced the completion of enrollment in the ATMOSPHERE® and ASCENT® pivotal studies …
Full Summary
|
RGNX REGENXBIO |
$12.22
+16.3% |
+28.9%
|
surabgene lomparvovec
for Wet AMD
|
Target date: Q4 2026
|
10/6/2025 - Top-line data
REGENXBIO Inc. announced that Topline pivotal data expected in Q4 2026
Full Summary
|
CNTX Context Therapeutics |
$1.14
+0.9% |
+38.8%
 |
CT-95
For mesothelin-expressing cancers.
|
|
10/6/2025 - Poster Presentation
Context Therapeutics Inc. announced two posters will be presented at the Society for Immunotherapy o…
Full Summary
|
ARQT Arcutis Biotherapeutics |
$21.24
+3.3% |
+22.6%
 |
ZORYVE™ (roflumilast)
Inhibitor of phosphodiesterase-4 (PDE4)
|
supplemental New Drug Application (sNDA)
|
10/6/2025 - FDA approved
Arcutis Biotherapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approv…
Full Summary
|
HUMA Humacyte |
$1.69
+2.4% |
+19.9%
 |
Human Acellular Vessel
Coronary Artery Bypass Grafting
|
|
10/6/2025 - Publication
Humacyte, Inc. announced the publication in Oxford Academic's Military Medicine of positive long-ter…
Full Summary
|
SPRB Spruce Biosciences |
$160.08
-12.3% |
+1678.7%
 |
TA-ERT
for the treatment of Sanfilippo Syndrome Type B (MPS IIIB).
|
Breakthrough Therapy
|
10/6/2025 - Designation Grant
Spruce Biosciences, Inc announced that the U.S. Food and Drug Administration (FDA) has granted Brea…
Full Summary
|
ATOS Atossa Genetics |
$1.11
+9.9% |
+37.5%
 |
Z-endoxifen
Breast cancer in the neoadjuvant (prior to surgery) setting
|
Phase 2
|
10/6/2025 - Provided Update
Atossa Therapeutics, Inc. (announces an amendment to its Phase 2 EVANGELINE study of (Z)-endoxifen i…
Full Summary
|
GANX Gain Therapeutics |
$2.07
+2.5% |
+18.3%
 |
GT-02287
GBA1 Parkinson's disease
|
|
10/6/2025 - Poster Presentation
Gain Therapeutics, Inc. today presented a poster at the International Congress of Parkinson's Diseas…
Full Summary
|
NBIX Neurocrine Biosciences |
$139.08
+1.5% |
-3.3%
 |
INGREZZA (Valbenazine)
Tardive Dyskinesia
|
|
10/6/2025 - Data
Neurocrine Biosciences, Inc. today presented new data from the open-label KINECT®-HD2 study demonst…
Full Summary
|
EDIT Editas Medicine |
$4.15
+5.6% |
+48.7%
 |
EDIT-401
Gene and Cell Therapy
|
|
10/6/2025 - Oral presentation
Editas Medicine, Inc. announced an oral presentation at the upcoming European Society of Gene and C…
Full Summary
|
RNA Avidity Biosciences |
$48.26
+2.8% |
+0.4%
 |
EXPLORE44
in People Living with DMD44
|
|
10/6/2025 - Oral presentation
Avidity Biosciences, Inc. announced that it will deliver late-breaking oral and poster presentation…
Full Summary
|
RCUS Arcus Biosciences |
$15.05
+7.3% |
+31.7%
 |
ARC-20
In patients that had received both prior TKI and anti-PD-1 therapy.
|
|
10/6/2025 - Data
Arcus Biosciences, Inc announced new monotherapy data for casdatifan, a HIF-2a inhibitor with best…
Full Summary
|
NRSN NeuroSense Therapeutics |
$1.22
+6.1% |
+5.2%
 |
PrimeC
Amyotrophic lateral sclerosis
|
|
10/6/2025 - Findings Update
NeuroSense Therapeutics Ltd. announced new positive findings based on plasma samples from its Phase…
Full Summary
|
ABBV AbbVie |
$231.26
-0.7% |
+10.1%
 |
BOTOX (onabotulinumtoxinA)
Upper Limb Spasticity
|
Phase 2
|
10/6/2025 - Top-line results
AbbVie announced positive topline results from the Phase 2 ELATE trial evaluating the safety and eff…
Full Summary
|
KALV KalVista Pharmaceuticals |
$11.49
+5.2% |
-28.0%
 |
sebetralstat
Therapy for hereditary angioedema (HAE).
|
|
10/6/2025 - New Data
KalVista Pharmaceuticals, Inc announced new data from its KONFIDENT and KONFIDENT-S studies of EKTE…
Full Summary
|
BMEA Biomea Fusion |
$1.68
-9.2% |
-7.2%
 |
icovamenib
For 2 diabetes
|
|
10/6/2025 - Results
Biomea Fusion, Inc. announced positive 52-week results from its Phase II COVALENT-111 study evaluat…
Full Summary
|
BIIB Biogen |
$150.97
-0.8% |
+6.8%
 |
LEQEMBI® (lecanemab-irmb)
Treatment of Alzheimer's Disease
|
|
10/6/2025 - Provided Update
Eisai Co., Ltd. and Biogen Inc. announced that lecanemab-irmb subcutaneous injection (U.S. brand na…
Full Summary
|
DYN Dyne Therapeutics |
$14.56
+4.4% |
+9.5%
 |
DYNE-101
Designed to enable targeted muscle tissue delivery with the goal of reducing toxic DMPK RNA in the nucleus
|
Phase 1/2
|
10/6/2025 - Additional data
Dyne Therapeutics, Inc. announced additional one-year data from its ongoing Phase 1/2 ACHIEVE clinic…
Full Summary
|
ARVN Arvinas |
$9.75
+4.8% |
+22.8%
 |
ARV-102
PROTAC® degrader designed to target the LRRK2 protein
|
Phase 1
|
10/5/2025 - Positive Data
Arvinas, Inc. announced positive pharmacokinetic, pharmacodynamic, and biomarker data from two Phase…
Full Summary
|
OVID Ovid Therapeutics |
$1.58
-5.4% |
+27.4%
 |
OV329
In Treatment-Resistant Seizures
|
Phase 1
|
10/3/2025 - Top-line results
Ovid Therapeutics Inc. announced positive topline results from its Phase 1 healthy volunteer study …
Full Summary
|
ESPR Esperion Therapeutics |
$2.57
-16.8% |
+2.4%
 |
NEXLETOL
treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease
|
|
10/3/2025 - Provided Update
Esperion announced that it has entered into a settlement agreement with Dr. Reddy's Laboratories, I…
Full Summary
|
SRPT Sarepta Therapeutics |
$23.38
+1.1% |
+32.8%
 |
ELEVIDYS (delandistrogene moxeparvovec-rokl)
Designed to address the underlying cause of Duchenne muscular dystrophy through the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle.
|
|
10/3/2025 - Presentation
Sarepta Therapeutics, Inc will present at the 30th Annual Congress of the World Muscle Society (WMS…
Full Summary
|
XLO Xilio Therapeutics |
$0.84
+2.3% |
+20.9%
 |
XTX301
Solid tumors
|
|
10/3/2025 - Poster Presentation
Xilio Therapeutics, Inc. announced multiple upcoming poster presentations at the Society for Immun…
Full Summary
|
BCAB BioAtla |
$0.91
+14.9% |
+49.5%
 |
BA3011 (Mecbotamab Vedotin)
Solid Tumors
|
|
10/3/2025 - Clinical Data
BioAtla, Inc. announced that clinical data for its investigational AXL-targeting antibody-drug conju…
Full Summary
|
HOWL Werewolf Therapeutics |
$1.88
-2.6% |
+41.4%
|
WTX-124
Solid Tumors
|
|
10/3/2025 - Poster Presentation
Werewolf Therapeutics, Inc announced that three posters will be presented at the upcoming Society f…
Full Summary
|
ALXO ALX Oncology |
$1.97
+7.7% |
+77.5%
 |
ASPEN-06
In Patients With HER2-Positive Gastric Cancer
|
|
10/3/2025 - Updated data
ALX Oncology Holdings Inc nnounced updated data from its Phase 2 ASPEN-06 (NCT05002127) trial will b…
Full Summary
|
CHRS Coherus Oncology |
$1.76
+2.9% |
+28.5%
 |
CHS-114
In patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)
|
|
10/3/2025 - Upcoming presentations
Coherus Oncology announced an upcoming poster presentation at the 40th Annual Meeting of the Socie…
Full Summary
|
CADL Candel Therapeutics |
$6.30
+11.9% |
+23.5%
 |
CAN-2409
Prostate cancer
|
|
10/3/2025 - Presentation
Candel Therapeutics, Inc. announced the Company will present insights from its enLIGHTEN™ Discovery…
Full Summary
|
OVID Ovid Therapeutics |
$1.58
-5.4% |
+27.4%
|
OV329
In Treatment-Resistant Seizures
|
Phase 1
|
10/3/2025 - Top-line results
Ovid Therapeutics Inc. announced positive topline results from its Phase 1 healthy volunteer study …
Full Summary
|
IMRN IMMURON |
$2.27
+13.3% |
+21.1%
|
Travelan
To prevent infectious diarrhea caused by enterotoxigenic Escherichia coli (ETEC).
|
|
10/2/2025 - Provided Update
Immuron Limited is pleased to provide shareholders with a brief update on progress with a number of…
Full Summary
|
AVXL Anavex Life Sciences |
$9.85
+0.7% |
+5.3%
 |
ANAVEX®3-71
For the treatment of neurodegenerative and neurodevelopmental disorders
|
Phase 2
|
10/2/2025 - Top-line results
Anavex Life Sciences Corp. announced positive topline results from its placebo-controlled Phase 2 c…
Full Summary
|
ATHE Alterity Therapeutics |
$4.31
+0.7% |
-16.6%
 |
ATH434-201
Investigation of ATH434 in patients with early-stage multiple system atrophy (MSA), a rare neurodegenerative disease with no approved treatments to slow or stop its progression.
|
|
10/2/2025 - Data
Alterity Therapeutics announced that data from the ATH434-201 randomized, double-blind Phase 2 cli…
Full Summary
|
ATXS Astria Therapeutics |
$8.40
+12.4% |
+13.1%
|
Navenibart
For the Treatment of Hereditary Angioedema
|
Phase 3
|
10/2/2025 - Clinical Trial
Astria Therapeutics, Inc announced that it has begun opening clinical trial sites in the European Un…
Full Summary
|
TSHA Taysha Gene Therapies |
$5.06
+7.2% |
+56.2%
 |
TSHA-102
Rett Syndrome
|
Breakthrough Therapy
|
10/2/2025 - Designation Grant
Taysha Gene Therapies, Inc. announced the U.S. Food and Drug Administration (FDA) has granted Break…
Full Summary
|
URGN Urogen Pharma |
$17.33
+2.9% |
-19.1%
 |
ZUSDURI
for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
|
|
10/2/2025 - Publication
UroGen Pharma Ltd. announced the publication of a comprehensive review of the clinical development …
Full Summary
|
HOLX Hologic |
$68.34
+0.9% |
+2.7%
 |
Panther Fusion® Gastrointestinal (GI) Bacterial and Expanded Bacterial Assays.
Detect Common Causes of Infectious Gastroenteritis
|
|
10/2/2025 - FDA Clearance
Hologic, Inc announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearanc…
Full Summary
|
SNY Sanofi |
$48.80
-0.8% |
+4.3%
 |
T1D 4-plex
diabetic ketoacidosis (DKA)
|
|
10/2/2025 - Provided Update
Revvity, Inc. announced a program for expansion of its type 1 diabetes (T1D) offering to include a …
Full Summary
|
RVTY Revvity |
$91.90
+0.8% |
+6.5%
 |
T1D 4-plex
diabetic ketoacidosis (DKA)
|
|
10/2/2025 - Provided Update
Revvity, Inc. announced a program for expansion of its type 1 diabetes (T1D) offering to include a …
Full Summary
|
EWTX Edgewise Therapeutics |
$15.35
+1.4% |
+3.2%
 |
sevasemten
For Becker muscular dystrophy
|
|
10/2/2025 - Provided Update
Edgewise Therapeutics, Inc., announced its participation at the 30th International Annual Congress …
Full Summary
|
SSII SS Innovations International |
$6.73
-0.7% |
+9.6%
 |
SSi Mantra surgical robotic system
robotic surgery
|
|
10/2/2025 - Provided Update
SS Innovations International announced that the Company successfully completed a human factors vali…
Full Summary
|
SSII SS Innovations International |
$6.73
-0.7% |
+9.6%
|
SSi Mantra surgical robotic system
robotic surgery
|
Target date: Q4 2025
|
10/2/2025 - Pre-Marketing Filing
SS Innovations International anticipates submitting a 510(k) premarket notification to the United …
Full Summary
|
AMGN Amgen |
$294.62
-0.3% |
+5.2%
 |
Repatha (Evolocumab)
HIV who have high cholesterol, as well as new data from FOURIER evaluating biomarkers of major cardiovascular (CV) events
|
Phase 3
|
10/2/2025 - Endpoint Met
Amgen announced the Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints demonstrating …
Full Summary
|
ACAD ACADIA Pharmaceuticals |
$21.31
-1.1% |
-16.1%
 |
ACP-711
GABRA3 modulators
|
|
10/2/2025 - Late Breaking Presentation
Acadia Pharmaceuticals Inc announced one late-breaker oral platform presentation and two poster pr…
Full Summary
|
JAZZ Jazz Pharmaceuticals |
$137.78
+0.3% |
+6.1%
 |
Zepzelca (lurbinectedin)
Relapsed Small Cell Lung Cancer (SCLC)
|
|
10/2/2025 - FDA approved
Jazz Pharmaceuticals announced that the Food and Drug Administration approved lurbinectedin
Full Summary
|
SVRA Savara |
$3.47
+1.2% |
-9.9%
 |
Molgramostim (IMPALA-2)
Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
|
|
10/2/2025 - Poster Presentation
Savara Inc. announced the acceptance of two abstracts for poster presentation and one abstract as an…
Full Summary
|
MESO Mesoblast |
$19.75
+9.2% |
+35.7%
 |
RYONCIL
For the treatment of severe and life-threatening inflammatory conditions.
|
|
10/2/2025 - Provided Update
Mesoblast Limited announced that a specific Healthcare Common Procedure Coding System (HCPCS) J-Code…
Full Summary
|
CDTX Cidara Therapeutics |
$98.51
-3.6% |
+58.5%
 |
CD388
Universal Prevention and Treatment of Influenza
|
|
10/2/2025 - Provided Update
Cidara Therapeutics, Inc. announced it has received an award valued up to $339M from the Biomedical…
Full Summary
|
PHAR Pharming Group |
$14.77
+0.6% |
-0.2%
 |
Leniolisib
Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)
|
supplemental New Drug Application (sNDA)
|
10/1/2025 - FDA Accepted
Pharming Group N.V. announced that the U.S. Food and Drug Administration (FDA) has accepted its sup…
Full Summary
|
BMY Bristol Myers Squibb |
$44.55
-0.2% |
-4.6%
 |
BMS-986446
Treatment of Alzheimer's Disease
|
Fast Track
|
10/1/2025 - Designation Grant
Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted Fast Tr…
Full Summary
|
ARVN Arvinas |
$9.75
+4.8% |
+22.8%
|
ARV-102
PROTAC® degrader designed to target the LRRK2 protein
|
|
10/1/2025 - Presentation
Arvinas, Inc. announced that two presentations, including one e-poster session and one oral platform…
Full Summary
|
AZN AstraZeneca |
$85.38
-0.6% |
+4.7%
|
ENHERTU® (fam-trastuzumab deruxtecan-nxki)
For the treatment of adult patients with unresectable or metastatic HER2 positive
|
BLA
|
10/1/2025 - FDA Accepted
Daiichi Sankyo and AstraZeneca announced that the supplemental Biologics License Application (sBL…
Full Summary
|
KURA Kura Oncology |
$10.08
+6.9% |
+23.8%
 |
KOMET-007
Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
|
|
10/1/2025 - Dose Update
Kura Oncology, Inc and Kyowa Kirin Co., Ltd. announced dosing of the first patient in a cohort of …
Full Summary
|
ALNY Alnylam Pharmaceuticals |
$450.68
-1.9% |
-1.0%
 |
Zilebesiran (ALN-AGT)
Mild-to-Moderate Hypertension
|
Phase 3
|
10/1/2025 - Dosing Update
Alnylam Pharmaceuticals, Inc announced that the first patient has been dosed in ZENITH (ZilebEsiraN…
Full Summary
|
RADX Radiopharm Theranostics |
$7.54
+7.1% |
+30.0%
 |
RAD202
to treat HER2-positive advanced and metastatic cancers
|
|
10/1/2025 - Recommendation
Radiopharm Theranostics announced that it has received a positive recommendation from the Data Safe…
Full Summary
|
ADGM Adagio Medical |
$2.25
-4.7% |
+61.9%
 |
FULCRUM-VT
for Ventricular Tachycardia
|
|
10/1/2025 - Enrollment Update
Adagio Medical Holdings, Inc announced the completion of enrollment of the FULCRUM-VT Pivotal U.S. …
Full Summary
|
MLTX MoonLake Immunotherapeutics |
$9.10
-1.9% |
-85.1%
 |
Sonelokimab
Moderate-to-severe hidradenitis suppurativa
|
|
10/1/2025 - Provided Update
MoonLake Immunotherapeutics nnounced disastrous VELA-2 trial results for sonelokimab, its highly an…
Full Summary
|
FBIO Fortress Biotech |
$2.91
-4.6% |
-19.2%
 |
CUTX-101
Menkes disease
|
|
10/1/2025 - Complete Response Letter
Fortress Biotech, Inc. announced that the U.S. Food and Drug Administration ("FDA") has issued a Co…
Full Summary
|
CAMP CAMP4 Therapeutics |
$3.47
-7.1% |
+110.5%
 |
CMP-SYNGAP-01
Treatment rescued multiple SYNGAP1-dependent behavioral phenotypes
|
|
10/1/2025 - Study Initiation
CAMP4 Therapeutics announced the initiation of toxicology studies conducted under Good Laboratory P…
Full Summary
|
SLDB Solid Biosciences |
$6.31
+14.3% |
+23.0%
 |
SGT-003
For Duchenne Muscular Dystrophy Gene Therapy
|
|
10/1/2025 - Presentation
Solid Biosciences Inc. will present data from its neuromuscular and cardiac programs at the World M…
Full Summary
|
CRSP CRISPR Therapeutics |
$76.78
+8.7% |
+41.9%
 |
SyNTase
Gene Editing Technology
|
|
10/1/2025 - Presentation
CRISPR Therapeutics To Present Preclinical Data On Alpha-1 Antitrypsin Deficiency Utilizing Novel Sy…
Full Summary
|
ASBP Aspire Biopharma |
$0.36
+1.4% |
-28.8%
 |
Sublingual Aspirin
Diabetes, Weight Management
|
|
10/1/2025 - Provided Update
Aspire Biopharma Holdings, announced pipeline progress and key milestones expected through the remai…
Full Summary
|
RCEL Avita Medical |
$5.51
+0.7% |
+30.9%
 |
RECELL System
Extensive Burns and Pediatric Patients
|
|
10/1/2025 - Provided Update
AVITA Medical®, Inc. announced that beginning October 1, 2025, hospitals across the U.S. will be el…
Full Summary
|
